A Case of Muir-Torre Syndrome
- PMID: 34036002
- PMCID: PMC8136295
- DOI: 10.7759/cureus.14582
A Case of Muir-Torre Syndrome
Abstract
Muir-Torre syndrome (MTS) is an autosomal dominant condition characterized by dermatological tumors along with visceral malignancies. The dermatological manifestations include recurrent sebaceous adenomas and keratoacanthomas. The commonly seen visceral malignancies are colorectal, gynecological, and urological. It is a variant of hereditary non-polyposis colorectal carcinoma syndrome (HNPCC). The underlying genetic mechanism is germline mutations in the DNA mismatch repair (MMR) genes leading to microsatellite instability (MSI), conferring an increased risk of developing malignancies. This is a case of a 57-year-old male patient with a history of colon cancer diagnosed at age 32 and multiple sebaceous adenomas. The patient also has a strong family history of cancer. They were referred to oncology after the immunohistochemical staining of a sebaceous adenoma showed loss of expression for MSH2 and MSH6. Next-generation sequencing identified a mutation in the MSH2 gene. These patients require genetic testing, counseling, and close follow-up with regular screening for cancer.
Keywords: colon cancer; hnpcc; lynch syndrome; mismatch repair genes; muir-torre syndrome.
Copyright © 2021, Sheth et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures



Similar articles
-
Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.Cureus. 2023 Jan 19;15(1):e33975. doi: 10.7759/cureus.33975. eCollection 2023 Jan. Cureus. 2023. PMID: 36824550 Free PMC article.
-
Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.Gene. 2016 Sep 10;589(2):127-32. doi: 10.1016/j.gene.2015.06.078. Epub 2015 Jul 2. Gene. 2016. PMID: 26143115 Review.
-
Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.J Invest Dermatol. 2006 Oct;126(10):2302-7. doi: 10.1038/sj.jid.5700475. Epub 2006 Jul 6. J Invest Dermatol. 2006. PMID: 16826164
-
Sebaceous Carcinoma as a Presentation of Muir-Torre Syndrome.Cureus. 2025 Jan 13;17(1):e77386. doi: 10.7759/cureus.77386. eCollection 2025 Jan. Cureus. 2025. PMID: 39949456 Free PMC article.
-
MSH6, Past and Present and Muir-Torre Syndrome-Connecting the Dots.Am J Dermatopathol. 2017 Apr;39(4):239-249. doi: 10.1097/DAD.0000000000000633. Am J Dermatopathol. 2017. PMID: 28323777 Review.
Cited by
-
Liquid Biopsy as a Source of Nucleic Acid Biomarkers in the Diagnosis and Management of Lynch Syndrome.Int J Mol Sci. 2022 Apr 13;23(8):4284. doi: 10.3390/ijms23084284. Int J Mol Sci. 2022. PMID: 35457101 Free PMC article. Review.
References
-
- Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Muir EG, Bell AJ, Barlow KA. Br J Surg. 1967;54:191–195. - PubMed
-
- Multiple sebaceous tumors. Torre D. https://pubmed.ncbi.nlm.nih.gov/5684233/ Arch Dermatol. 1968;98:549–551. - PubMed
-
- Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. Abbas O, Mahalingam M. http:// https://doi.org/10.1111/j.1600-0560.2009.01248.x. J Cutan Pathol. 2009;36:613–619. - PubMed
-
- Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome. Machin P, Catasus L, Pons C, et al. http:// https://doi.org/10.1034/j.1600-0560.2002.290705.x. J Cutan Pathol. 2002;29:415–420. - PubMed
-
- A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome. Perera S, Ramyar L, Mitri A, et al. J Hum Genet. 2010;55:37–41. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous